AbbVie (ABBV) on Thursday said that Canada's Drug Agency (CDA-AMC) has recommended ELAHERE for reimbursement with conditions for the treatment of patients with certain types of platinum-resistant ovarian cancer.
The company noted that ELAHERE was submitted for reimbursement review 180 days before Health Canada's approval, in alignment with CDA-AMC's Target Zero initiative, which aims to accelerate patient access to new therapies.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.